TXA is an inexpensive (approximately $3 per gram) and widely available antifibrinolytic medication with an established safety ...

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

The use of an older medication at the time of surgery can reduce the need for red blood cell transfusions, according to a ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

On Wednesday, the Nobel Prize will be awarded in Oslo - an important date for the royal family. In recent days, the royals ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its ...

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...

Renal denervation (RDN) is a minimally invasive procedure used as an adjunctive treatment for individuals with resistant ...

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investi ...